vs
Side-by-side financial comparison of SITIME Corp (SITM) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $113.6M, roughly 1.4× SITIME Corp). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 88.3%).
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
SITM vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.6M | $158.6M |
| Net Profit | — | $112.9M |
| Gross Margin | 59.0% | — |
| Operating Margin | 30.2% | 70.2% |
| Net Margin | — | 71.2% |
| Revenue YoY | 88.3% | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $-0.20 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $113.6M | — | ||
| Q4 25 | $113.3M | — | ||
| Q3 25 | $83.6M | — | ||
| Q2 25 | $69.5M | — | ||
| Q1 25 | $60.3M | $158.6M | ||
| Q4 24 | $68.1M | $22.6M | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $43.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $9.2M | — | ||
| Q3 25 | $-8.0M | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-23.9M | $112.9M | ||
| Q4 24 | $-18.8M | $-10.5M | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $-26.8M | — |
| Q1 26 | 59.0% | — | ||
| Q4 25 | 56.4% | — | ||
| Q3 25 | 53.5% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.3% | — | ||
| Q4 24 | 52.6% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.1% | — |
| Q1 26 | 30.2% | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | -19.2% | — | ||
| Q2 25 | -35.4% | — | ||
| Q1 25 | -46.6% | 70.2% | ||
| Q4 24 | -33.8% | -60.4% | ||
| Q3 24 | -43.1% | — | ||
| Q2 24 | -73.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | -9.6% | — | ||
| Q2 25 | -29.0% | — | ||
| Q1 25 | -39.6% | 71.2% | ||
| Q4 24 | -27.6% | -46.4% | ||
| Q3 24 | -33.5% | — | ||
| Q2 24 | -61.0% | — |
| Q1 26 | $-0.20 | — | ||
| Q4 25 | $0.44 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $-0.84 | — | ||
| Q1 25 | $-1.01 | $1.90 | ||
| Q4 24 | $-0.80 | $-0.15 | ||
| Q3 24 | $-0.83 | — | ||
| Q2 24 | $-1.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $350.1M |
| Total Assets | $1.3B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $498.5M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $692.5M | $350.1M | ||
| Q4 24 | $699.7M | $229.0M | ||
| Q3 24 | $696.2M | — | ||
| Q2 24 | $692.5M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $872.1M | $406.9M | ||
| Q4 24 | $885.0M | $271.6M | ||
| Q3 24 | $877.9M | — | ||
| Q2 24 | $878.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $25.4M | — | ||
| Q3 25 | $31.4M | — | ||
| Q2 25 | $15.3M | — | ||
| Q1 25 | $15.0M | $131.8M | ||
| Q4 24 | $13.5M | $-23.2M | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-181.0K | — |
| Q1 26 | — | — | ||
| Q4 25 | $13.0M | — | ||
| Q3 25 | $26.3M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-1.3M | $131.7M | ||
| Q4 24 | $-2.4M | $-23.2M | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-2.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.5% | — | ||
| Q3 25 | 31.5% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -2.1% | 83.0% | ||
| Q4 24 | -3.5% | -102.7% | ||
| Q3 24 | -11.6% | — | ||
| Q2 24 | -6.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 26.2% | — | ||
| Q1 25 | 27.0% | 0.1% | ||
| Q4 24 | 23.3% | 0.2% | ||
| Q3 24 | 25.7% | — | ||
| Q2 24 | 5.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.77× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
